Last reviewed · How we verify
PH009-1 tablet
At a glance
| Generic name | PH009-1 tablet |
|---|---|
| Also known as | PH009-1 |
| Sponsor | Suzhou Puhe Pharmaceutical Technology Co., LTD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PH009-1 tablet CI brief — competitive landscape report
- PH009-1 tablet updates RSS · CI watch RSS
- Suzhou Puhe Pharmaceutical Technology Co., LTD portfolio CI